Antimicrobial Agents Practice Questions

Q: What is the drug of choice for listeria meningitis?

Ampicillin. ***Ampicillin*** - **Ampicillin** is the **drug of choice** for *Listeria monocytogenes* meningitis due to its excellent in vitro activity and good central nervous system penetration. - It is often used in combination with an **aminoglycoside** (e.g., gentamicin) for synergistic bactericidal activity, especially in severe cases, though gentamicin does not penetrate the CSF well. *Cefotaxime* - **Third-generation cephalosporins** like cefotaxime have poor activity against *Listeria monocytogenes* due to the organism's intrinsic resistance to these agents. - While effective against many other bacterial causes of meningitis (e.g., *S. pneumoniae*, *N. meningitidis*), it is not appropriate for *Listeria*. *Ceftriaxone* - Similar to cefotaxime, **ceftriaxone** is a third-generation cephalosporin and is **ineffective** against *Listeria monocytogenes* due to the lack of penicillin-binding protein (PBP) affinity. - Its use for *Listeria* meningitis would lead to treatment failure. *Ciprofloxacin* - **Ciprofloxacin**, a fluoroquinolone, is generally **not recommended** as a first-line treatment for *Listeria* meningitis, despite some in vitro activity. - Its use is typically reserved for patients with severe allergies to penicillins, and even then, **trimethoprim-sulfamethoxazole** is usually preferred as an alternative to ampicillin.

Q: What is the drug of choice for malaria in pregnancy?

Chloroquine. ***Chloroquine*** - **Chloroquine** is the drug of choice for **uncomplicated malaria in pregnancy** caused by **chloroquine-sensitive** strains of *P. vivax*, *P. ovale*, *P. malariae*, and *P. falciparum* [1]. - It has an **established safety profile** in pregnancy across all trimesters and is considered safe by WHO and CDC. - While resistance has emerged in many areas for *P. falciparum*, chloroquine remains effective for *P. vivax* malaria in most regions including India. - For **severe malaria** or **chloroquine-resistant falciparum malaria**, alternative regimens like quinine or artesunate are used [1]. *Quinine* - **Quinine** (usually with clindamycin) is the preferred treatment for **severe malaria** or **chloroquine-resistant *P. falciparum*** malaria in pregnancy, especially in the **first trimester**. - It is safe and effective but can cause side effects like **cinchonism** (tinnitus, headache, nausea) and **hypoglycemia**. - While safe throughout pregnancy, it is not the first-line choice for uncomplicated chloroquine-sensitive malaria. *Primaquine* - **Primaquine** is **contraindicated in pregnancy** because it can cause **hemolytic anemia** in individuals with **G6PD deficiency**, and G6PD status of the fetus cannot be determined [3]. - It is used for **radical cure** of *P. vivax* and *P. ovale* to eliminate liver hypnozoites, but must be deferred until after delivery [3]. *Artesunate* - **Artesunate** and other **artemisinin-based combination therapies (ACTs)** are highly effective antimalarials [2]. - Current WHO guidelines support ACT use in all trimesters for severe malaria when benefits outweigh risks. - For **uncomplicated falciparum malaria**, ACTs are preferred in the **second and third trimesters** in areas with chloroquine resistance [2]. - However, chloroquine remains the classical "drug of choice" for uncomplicated, chloroquine-sensitive malaria in pregnancy [1].

Q: Which of the following drugs does not inhibit bacterial protein synthesis?

Sulfonamides. ***Sulfonamides*** - Sulfonamides do **NOT** inhibit bacterial protein synthesis; instead, they inhibit **folic acid synthesis**. - They act as **competitive inhibitors** of dihydropteroate synthase, an enzyme involved in the synthesis of dihydrofolic acid. - Folic acid is essential for nucleotide synthesis and DNA replication, making sulfonamides bacteriostatic agents that work through a completely different mechanism than protein synthesis inhibitors. *Aminoglycosides* - Aminoglycosides bind to the **30S ribosomal subunit**, causing misreading of mRNA and premature termination of protein synthesis. - This leads to the production of **abnormal and non-functional proteins**, ultimately killing the bacterial cell. *Chloramphenicol* - Chloramphenicol binds to the **50S ribosomal subunit**, thereby inhibiting the peptidyl transferase enzyme. - This prevents the formation of **peptide bonds** between amino acids, effectively blocking protein elongation. *Clindamycin* - Clindamycin also binds to the **50S ribosomal subunit**, specifically at the P-site. - It interferes with the **translocation step** of protein synthesis, preventing ribosomal movement along the mRNA.

Q: What is the primary purpose of administering a multidrug regimen for tuberculosis (TB) treatment?

To prevent the development of drug resistance. ***To prevent the development of drug resistance*** - Using multiple drugs simultaneously targets different bacterial pathways, reducing the likelihood of *Mycobacterium tuberculosis* evolving resistance to any single drug [1] - This strategy ensures that even if a few bacteria are naturally resistant to one drug, other drugs in the regimen will eliminate them [1] - This is the fundamental principle behind multidrug TB therapy as per WHO guidelines *To provide broad-spectrum coverage* - TB treatment uses multiple drugs specifically against *Mycobacterium tuberculosis*, not for broad-spectrum coverage [2] - These regimens are tailored to the known characteristics of TB bacteria, not to cover a wide range of pathogens [2] - The drugs used (rifampicin, isoniazid, pyrazinamide, ethambutol) are relatively specific for mycobacteria [2] *To minimize side effects* - Administering multiple anti-TB drugs actually increases the risk of cumulative side effects due to drug interactions and individual toxicities [3] - Each drug has its own toxicity profile (hepatotoxicity, optic neuritis, hyperuricemia) [3] - While side effects are monitored, minimizing them is not the primary reason for multidrug approach *To ensure treatment adherence* - Treatment adherence refers to the patient's consistent use of prescribed medications, not the number of drugs - A complex multidrug regimen can actually make adherence more challenging - Directly Observed Therapy (DOT) is often needed to improve adherence with multidrug regimens

Q: What is the mechanism of action of quinolones?

Inhibit DNA gyrase. ***Inhibit DNA gyrase*** - Quinolones, particularly **fluoroquinolones**, exert their bactericidal effect by targeting **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**. - This inhibition prevents the uncoiling and replication of bacterial DNA, leading to cell death. *Bind to 30S ribosomal subunit* - This mechanism is characteristic of **aminoglycosides** and **tetracyclines**, which disrupt bacterial protein synthesis. - Quinolones do not interfere with ribosomal function but rather with **DNA replication**. *Bind to bacterial cell membrane* - This is the mechanism of action for **polymyxins** and **daptomycin**, which disrupt the integrity of the bacterial cell membrane. - Quinolones specifically target **intracellular enzymes** involved in DNA handling. *Inhibit tetrahydrofolate reductase* - This enzyme name in the option is technically imprecise; **trimethoprim** actually inhibits **dihydrofolate reductase**, which is part of the **sulfonamide-trimethoprim (Bactrim)** combination. - This pathway is involved in **folic acid synthesis**, crucial for bacterial DNA and RNA production, a mechanism distinct from quinolones.

Q: Which of the following is not used as treatment for lymphatic filariasis -

Praziquantel. ***Praziquantel*** - **Praziquantel** is primarily an **anthelmintic drug** effective against **schistosomiasis** and **tapeworm infections**. - It does not have a significant role in the treatment of **lymphatic filariasis**. *Ivermectin* - **Ivermectin** is one of the **mainstays** of treatment for **lymphatic filariasis**, particularly in combination therapies. - It works by paralyzing and killing **microfilariae**, reducing their numbers in the bloodstream. *DEC* - **Diethylcarbamazine (DEC)** is a **highly effective antifilarial drug** used to kill both **microfilariae** and **adult worms** in lymphatic filariasis. - It is often used in mass drug administration programs and for individual treatment. *Albendazole* - **Albendazole** is an **anthelmintic drug** often used in combination with **Ivermectin** or **DEC** for the treatment of **lymphatic filariasis**. - It helps to kill **microfilariae** and has some macrofilaricidal effects, reducing the viability of adult worms.

Q: What is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?

To decrease the risk of resistance due to mutation.. ***To decrease the risk of resistance due to mutation*** - **Tuberculosis bacteria** can spontaneously develop resistance to a single drug through **random genetic mutations**. - Using multiple drugs simultaneously significantly reduces the probability that a bacterium will spontaneously develop resistance to **all drugs** in the regimen. - This is the **primary rationale** for multi-drug therapy in TB, as emphasized by WHO guidelines. *To decrease the risk of resistance due to conjugation* - **Conjugation** is a mechanism of horizontal gene transfer in bacteria, primarily involving the transfer of plasmids. - While important for antibiotic resistance in some bacteria, it is **not the primary mechanism** of resistance development in *Mycobacterium tuberculosis*. - TB resistance develops mainly through **chromosomal mutations**, not plasmid transfer. *To enhance overall treatment efficacy* - While multi-drug regimens do enhance treatment efficacy by targeting different bacterial populations (actively dividing, slow-growing, dormant), this is a **consequence** of the multi-drug approach. - The **primary reason** for using four drugs specifically is to prevent the emergence of **drug-resistant mutants**. - Enhanced efficacy is achieved *because* resistance is prevented, making this a secondary benefit. *To simplify treatment* - A four-drug regimen actually makes treatment more **complex** due to multiple pills, potential drug interactions, and increased side effects. - The complexity is a necessary trade-off for **resistance prevention** and treatment success.

Q: What is the recommended dose of oseltamivir for a child aged 9 months?

3 mg/kg twice daily for 5 days. ***3 mg/kg twice daily for 5 days*** - For children aged **less than 1 year**, and weighing less than 15 kg, the recommended oseltamivir dose is **3 mg/kg** administered **twice daily** for 5 days. - This dosage regimen is effective in treating influenza and is based on studies of its **pharmacokinetics** and **efficacy** in this age group. *2 mg/kg twice daily for 5 days* - This dosage is **lower than recommended** for children under 1 year of age and may not achieve adequate therapeutic drug levels. - Subtherapeutic dosing could lead to **reduced antiviral efficacy** and potentially poorer clinical outcomes. *2.5 mg/kg twice daily for 5 days* - Similar to the 2 mg/kg dose, this is **below the standard recommendation** for infants and young children in this age bracket. - Inadequate dosing increases the risk of **treatment failure** and the development of **antiviral resistance**. *3.5 mg/kg twice daily for 5 days* - This dosage might be considered **higher than necessary** for a 9-month-old child and could potentially increase the risk of **adverse effects**. - While exact toxicities are rare within a reasonable range, adherence to recommended guidelines optimizes the **benefit-risk profile**.

Q: Sulphonamide injection causes decrease in folic acid by?

Inhibition through competition with substrate. ***Inhibition through competition with substrate***Sulphonamides are **structural analogs of p-aminobenzoic acid (PABA)**, a substrate crucial for dihydropteroate synthase [1, 2]. They competitively inhibit this enzyme, which synthesizes **dihydrofolic acid**, a precursor to **tetrahydrofolic acid (THF)**, thereby reducing folic acid production in bacteria [1, 2].*Inhibition without competition*This typically refers to **non-competitive inhibition**, where the inhibitor binds to an allosteric site and changes the enzyme's conformation, regardless of substrate concentration. Sulphonamides, however, specifically compete with PABA at the active site of **dihydropteroate synthase**.*Inhibition through a different site*This describes **allosteric inhibition** or non-competitive inhibition, where the inhibitor binds to a site other than the active site. Sulphonamides do not work through an allosteric mechanism; they directly interfere with the binding of PABA at the enzyme's active site.*Inhibition that does not involve the active site*This is another way to describe **non-competitive** or **allosteric inhibition**, where the inhibitor binds elsewhere on the enzyme, altering its function without directly blocking the active site. Sulphonamides' mechanism is distinct, as they closely resemble the natural substrate and directly compete for the active site of **dihydropteroate synthase**.

Question 1

What is the best skin disinfectant for central line insertion?

Accepted Answer

Chlorhexidine

Answer

Alcohol

Answer

Cetrimide

Answer

Povidone iodine

Question 2

What is the drug of choice for listeria meningitis?

Accepted Answer

Ampicillin

Answer

Cefotaxime

Answer

Ciprofloxacin

Answer

Ceftriaxone

Question 3

What is the drug of choice for malaria in pregnancy?

Accepted Answer

Chloroquine

Answer

Primaquine

Answer

Artesunate

Answer

Quinine

Question 4

Which of the following drugs does not inhibit bacterial protein synthesis?

Accepted Answer

Sulfonamides

Answer

Aminoglycosides

Answer

Chloramphenicol

Answer

Clindamycin

Question 5

What is the primary purpose of administering a multidrug regimen for tuberculosis (TB) treatment?

Accepted Answer

To prevent the development of drug resistance

Answer

To provide broad-spectrum coverage

Answer

To minimize side effects

Answer

To ensure treatment adherence

Question 6

What is the mechanism of action of quinolones?

Accepted Answer

Inhibit DNA gyrase

Answer

Inhibit tetrahydrofolate reductase

Answer

Bind to 30S ribosomal subunit

Answer

Bind to bacterial cell membrane

Question 7

Which of the following is not used as treatment for lymphatic filariasis -

Accepted Answer

Praziquantel

Answer

DEC

Answer

Albendazole

Answer

Ivermectin

Question 8

What is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?

Accepted Answer

To decrease the risk of resistance due to mutation.

Answer

To decrease the risk of resistance due to conjugation.

Answer

To enhance overall treatment efficacy.

Answer

To simplify treatment.

Question 9

What is the recommended dose of oseltamivir for a child aged 9 months?

Accepted Answer

3 mg/kg twice daily for 5 days

Answer

2 mg/kg twice daily for 5 days

Answer

2.5 mg/kg twice daily for 5 days

Answer

3.5 mg/kg twice daily for 5 days

Question 10

Sulphonamide injection causes decrease in folic acid by?

Accepted Answer

Inhibition through competition with substrate

Answer

Inhibition without competition

Answer

Inhibition through a different site

Answer

Inhibition that does not involve the active site

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?